Cryo Cell International (CCEL) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $7.82M versus $7.83M YoY; operating income rose to $2.19M and net income to $1.27M from $749K. 9M revenue was $23.28M, while net income rose to $1.87M.

• Recurring annual storage revenue grew 3% in Q3 and 9M, offset by new domestic specimen processing declines of 16% and 15%, respectively.

Financial highlights

• Q3 cost of sales fell 10% YoY to $1.61M; SG&A declined 3% to $3.78M, and R&D expense was $54K versus $62K.

• 9M cost of sales declined 12% to $4.95M; SG&A increased 5% to $13.41M, including a $1.98M increase in legal fees and expenses.

• 9M interest expense was $1.34M versus $1.58M; marketable-securities losses were $99K versus $605K.

Outlook and guidance

• Cash, marketable securities, operating cash flows and external capital sources are expected to fund known cash needs for at least 12 months; operating cash generation depends on revenue growth and discretionary expense management.

• Further investment in activities tied to Duke is paused pending resolution of the dispute; the clinic opening and Celle Corp. spinoff remain on hold.

• If revenue growth is not achieved, expenses exceed expectations or financing is unavailable, spending may need to be reduced or deferred, potentially affecting sales and development initiatives.